Smoking, vaping, nicotine products and liver enzymes: Implications for drug metabolism and medication management
Loading...
Unable to use the file because of accessibility barriers? Send us feedback
Publication Date
2026-10
Avondale Authors
Publisher
Avondale Research
DOI
Original
Rights
Version
Review Status
Not Peer Reviewed
Field of Education
06 Health
Field of Research
4206 Public health
Degree
Department
Faculty
Supervisor
Awarding Institution
Degree
Department
Faculty
Supervisor
Awarding Institution
Abstract
Changes in smoking, vaping or nicotine use should trigger a medication review, with particular attention to CYP1A2-affected medicines such as clozapine, olanzapine and theophylline, as well as medicines with a narrow therapeutic index. This underscores the importance of taking a comprehensive nicotine use history, in terms of amount, type and duration of use. Any changes in the pattern of use should prompt a careful review of medications where an interaction is likely.
Description
Research Statement
Keywords
Citation
Bittoun, R., Saba, M., Hardy, M., & Montebello, M. (2026). Smoking, vaping, nicotine products and liver enzymes: Implications for drug metabolism and medication management [Fact sheet]. Avondale Research.